%PDF-1.4
%
61 0 obj
<>
endobj
58 0 obj
<>
endobj
114 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-10-06T20:08:13Z
2024-03-28T17:35:24-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T17:35:24-07:00
application/pdf
Heather
2002-723.nov
uuid:0ec86935-1dd2-11b2-0a00-f108271d5700
uuid:0ec86937-1dd2-11b2-0a00-bf0000000000
endstream
endobj
47 0 obj
<>
endobj
48 0 obj
<>
endobj
62 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
25 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 41 0 R/Type/Page>>
endobj
132 0 obj
[136 0 R]
endobj
133 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.0051 Tc 0.1069 Tw 10 0 0 10 66 713.1616 Tm
[(W)39.8 (ith an increasing number of previous DMARD, MTX)]TJ
0.35899 Tw -1.2 -1.2 Td
[(survival is slightly lower)54.8 (. )17.7 (These patients may have an)]TJ
-0.01241 Tw 0 -1.2 TD
(increased susceptibility to any adverse events, or a decreased)Tj
0.0825 Tw T*
[(ef)17.7 (ficacy to DMARD due to more severe disease. )54.7 (Again the)]TJ
0.0658 Tw T*
(attending rheumatologist may have been of influence, since)Tj
0.0144 Tw T*
[(the way a rheumatologist deals with adverse events and ef)17.6 (fi-)]TJ
0.02499 Tw T*
(cacy in MTX may apply to other DMARD as well.)Tj
-0.00011 Tc 0.1488 Tw 1.2 -1.2 Td
[(Although age is negatively)64.8 (, and creatinine clearance is)]TJ
-0.01981 Tw -1.2 -1.2 Td
[(positively)64.8 (, related to the maximum MTX dose, they are both)]TJ
-0.00591 Tw T*
[(not related to MTX survival. )17.7 (This is in agreement with most)]TJ
0.1922 Tw T*
(other studies. Only in the study by Buchbinder and in a)Tj
0.1243 Tw T*
[(retrospective study concerning 453 RA)-319.5 (patients was treat-)]TJ
0.0593 Tw T*
(ment termination due to toxicity higher in patients aged 65)Tj
-0.00639 Tw T*
(years and over)Tj
0 Tc 0 Tw 6.5 0 0 6.5 112.1706 560.4615 Tm
[(10,1)56.7 (1)]TJ
-0.00011 Tc -0.00639 Tw 10 0 0 10 126.4268 557.1616 Tm
(. In our data, dividing patients into groups)Tj
0.1483 Tw -7.2427 -1.2 Td
(below or above 65 years of age, there was no significant)Tj
0.30791 Tw T*
[(dif)17.7 (ference \(p = 0.07\), despite a trend towards a better)]TJ
0.02499 Tw T*
(survival in the lower age group.)Tj
0.0649 Tw 1.2 -1.2 Td
(In conclusion, the MTX cumulative survival probability)Tj
0.084 Tw -1.2 -1.2 Td
[(in this retrospective study of a cohort of 1022 RA)-279.2 (patients)]TJ
-0.02161 Tw T*
(was 64% after 5 years, and 50% after 9 years. Folate supple-)Tj
0.2095 Tw T*
(mentation, and to a lesser extent prednisolone use, were)Tj
0.09081 Tw T*
[(strongly related to MTX survival. )17.6 (The rheumatologist also)]TJ
0.0845 Tw T*
(appeared to play a decisive role in duration of MTX treat-)Tj
0.0255 Tw T*
(ment, partly explained by patient characteristics but also by)Tj
0.02499 Tw T*
[(dif)17.7 (ferences in individual treatment strategies.)]TJ
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 391.1616 Tm
[(1.)-875.1 (Kremer JM, Phelps CT)73.9 (. Long-term prospective study of the use of)]TJ
1.675 -1.25 Td
(methotrexate in the treatment of rheumatoid arthritis. Update after a)Tj
0 -1.25 TD
[(mean of 90 months. )54.8 (Arthritis Rheum 1992;35:138-45. )]TJ
-1.675 -1.25 Td
[(2.)-875.1 (W)79.9 (einblatt ME, Maier )54.8 (AL, Fraser P)91.7 (A, Coblyn JS. Longterm )]TJ
1.675 -1.25 Td
(prospective study of methotrexate in rheumatoid arthritis: )Tj
T*
[(conclusion after 132 months of therapy)64.8 (. J Rheumatol )]TJ
0 Tc 0 Tw T*
(1998;25:238-42.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Meenan RF)79.7 (. )17.7 (The comparative ef)17.7 (ficacy and)]TJ
1.675 -1.25 Td
(toxicity of second-line drugs in rheumatoid arthritis. Results of two)Tj
T*
[(metaanalyses. )54.8 (Arthritis Rheum 1990;33:1449-61.)]TJ
-1.675 -1.225 Td
[(4.)-875.1 (Jeurissen MEC, Boerbooms )54.8 (AMT)73.9 (, van de Putte LBA, et al.)]TJ
1.675 -1.225 Td
(Methotrexate versus azathioprine in the treatment of rheumatoid)Tj
0 -1.225 TD
(arthritis: a forty-eight-week randomized, double-blind trial.)Tj
T*
(Arthritis Rheum 1991;34:961-72.)Tj
-1.675 -1.225 Td
[(5.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley DJ, Cathey MA. )17.7 (T)69.9 (ermination of slow acting)]TJ
1.675 -1.225 Td
(antirheumatic therapy in rheumatoid arthritis: a 14-year prospective)Tj
T*
(evaluation of 1017 consecutive starts. J Rheumatol )Tj
0 Tc 0 Tw T*
(1990;17:994-1002.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.225 Td
[(6.)-875.1 (Morand EF)79.7 (, McCloud PI, Littlejohn GO. Life table analysis of 879)]TJ
1.675 -1.225 Td
(treatment episodes with slow acting antirheumatic drugs in )Tj
T*
(community rheumatology practice. J Rheumatol 1992;19:704-8.)Tj
-1.675 -1.225 Td
[(7.)-875.1 (Pincus )17.7 (T)74 (, Marcum SB, Callahan LF)79.7 (. Longterm drug therapy for)]TJ
1.675 -1.225 Td
(rheumatoid arthritis in seven rheumatology private practices: II.)Tj
T*
(second line drugs and prednisone. J Rheumatol 1992;19:1885-94. )Tj
-1.675 -1.225 Td
[(8.)-875.1 (Galindo-Rodriguez G, )54.8 (A)74 (vina-Zubieta JA, Russell )54.8 (AS, )]TJ
1.675 -1.225 Td
(Suarez-Almazor ME. Disappointing longterm results with disease )Tj
T*
[(modifying antirheumatic drugs. )54.8 (A)-220.1 (practice based study)64.8 (. )]TJ
T*
(J Rheumatol 1999;26:2337-43.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Alarcon GS, )17.7 (T)35 (racey IC, Blackburn )17.7 (WD Jr)54.8 (. Methotrexate in )]TJ
1.675 -1.25 Td
[(rheumatoid arthritis. )17.7 (T)69.9 (oxic ef)17.7 (fects as the major factor in limiting)]TJ
0 -1.25 TD
[(long-term treatment. )54.8 (Arthritis Rheum 1989;32:671-6.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Buchbinder R, Hall S, Sambrook PN, et al. Methotrexate therapy in)]TJ
2.175 -1.25 Td
(rheumatoid arthritis: a life table review of 587 patients treated in)Tj
33 79.9709 Td
(community practice. J Rheumatol 1993;20:639-44.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Bologna C, )17.7 (V)59.8 (iu P)110.7 (, Picot MC, Jor)17.7 (gensen C, Sany J. Long-term)]TJ
2.1381 -1.25 Td
(follow-up of 453 rheumatoid arthritis patients treated with)Tj
T*
[(methotrexate: an open, retrospective, observational study)64.8 (. Br )]TJ
T*
(J Rheumatol 1997;36:535-40.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Sany J, )54.8 (Anaya JM, Lussiez )17.7 (V)128.9 (, Couret M, Combe B, Daures JP)110.7 (.)]TJ
2.175 -1.25 Td
[(T)35 (reatment of rheumatoid arthritis with methotrexate: a prospective)]TJ
T*
(open longterm study of 191 cases. J Rheumatol 1991;18:1323-7.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (W)79.9 (einblatt ME, Kaplan H, Germain BF)79.7 (, et al. Methotrexate in)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis. )54.8 (A)-220.1 (five-year prospective multicenter study)64.8 (.)]TJ
T*
(Arthritis Rheum 1994;37:1492-8.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Alarcon GS, )17.7 (T)35 (racey IC, Strand GM, Singh K, Macaluso M.)]TJ
2.175 -1.25 Td
[(Survival and drug discontinuation analyses in a lar)17.7 (ge cohort of)]TJ
T*
[(methotrexate treated rheumatoid arthritis patients. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1995;54:708-12.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Ortendahl M, Schettler JD, Fries JF)79.7 (. Factors influencing length of)]TJ
2.175 -1.25 Td
(time taking methotrexate in rheumatoid arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
[(2000;27:1)36.9 (139-47.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Papadopoulos NG, )54.8 (Alamanos )36.8 (Y)128.9 (, Papadopoulos IA, )17.7 (T)69.9 (sifetaki N,)]TJ
2.175 -1.25 Td
[(V)128.9 (oulgari PV)128.8 (, Drosos )54.8 (AA. Disease modifying antirheumatic drugs in)]TJ
T*
[(early rheumatoid arthritis: a longterm observational study)64.8 (. )]TJ
T*
(J Rheumatol 2002;29:261-6.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Scully CJ, )54.8 (Anderson CJ, Cannon GW)91.7 (. Long-term methotrexate)]TJ
2.175 -1.25 Td
[(therapy for rheumatoid arthritis. Semin )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1991;20:317-31.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (De La Mata J, Blanco FJ, Gomez-Reino JJ. Survival analysis of)]TJ
2.175 -1.25 Td
(disease modifying antirheumatic drugs in Spanish rheumatoid)Tj
0 Tc T*
[(arthritis patients. )54.8 (Ann Rheum Dis 1995;54:881-5.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (Wluka )54.8 (A, Buchbinder R, Mylvaganam )54.8 (A, et al. Longterm)]TJ
2.175 -1.25 Td
(methotrexate use in rheumatoid arthritis: 12 year followup of 460)Tj
T*
(patients treated in community practice. J Rheumatol )Tj
0 Tc 0 Tw T*
(2000;27:1864-71.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (van Ede )54.8 (AE, Laan RFJM, Rood MJ, et al. Ef)17.7 (fect of folic or folinic)]TJ
2.175 -1.25 Td
[(acid supplementation on the toxicity and ef)17.7 (ficacy of methotrexate)]TJ
T*
[(in rheumatoid arthritis: a forty-eight week, multicenter)39.7 (, )]TJ
T*
[(randomized, double-blind, placebo-controlled study)64.8 (. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2001;44:1515-24.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21. )-600.1 (Cockcroft DW)91.7 (, Gault MH. Prediction of creatinine clearance from)]TJ
2.175 -1.25 Td
(serum creatinine. Nephron 1976;16:31-41.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Cabana MD, Rand CS, Powe NR, et al. )17.7 (Why don\325)17.7 (t physicians)]TJ
2.175 -1.25 Td
[(follow clinical practice guidelines? )54.8 (A)-220.1 (framework for improvement.)]TJ
0 Tc 0 Tw T*
[(JAMA)-220.1 (1999;282:1458-65.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Kirwan JR, Chaput de Saintonge DM, Joyce CRB, Holmes J,)]TJ
2.175 -1.25 Td
[(Currey HLF)79.7 (. Inability of rheumatologists to describe their true )]TJ
T*
[(policies for assessing rheumatoid arthritis. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1986;45:156-61.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Kerstens PJSM, Boerbooms )54.8 (AMT)73.9 (, Brummelkamp EP)110.7 (, van de Putte)]TJ
2.175 -1.25 Td
(LBA. Long-term methotrexate in refractory rheumatoid arthritis;)Tj
T*
(concurrent use of prednisone possibly improves drug-survival. Clin)Tj
T*
(Rheumatol 1994;13:317-8.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Boers M, )17.7 (V)110.8 (erhoeven )54.8 (AC, Markusse HM, et al. Randomised)]TJ
2.175 -1.25 Td
(comparison of combined step-down prednisolone, methotrexate and)Tj
T*
(sulphasalazine with sulphasalazine alone in early rheumatoid)Tj
T*
(arthritis. Lancet 1997;350:309-18.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (O\325Dell JR, Haire CE, Erikson N, et al. )17.7 (T)35 (reatment of rheumatoid)]TJ
2.175 -1.25 Td
(arthritis with methotrexate alone, sulfasalazine and )Tj
T*
(hydroxychloroquine, or a combination of all three medications. )Tj
0 Tc T*
(N Engl J Med 1996;334:1287-91.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(27.)-875.1 (Haagsma CJ, van Riel PLCM, de Jong )54.8 (AJL, van de Putte LBA.)]TJ
2.175 -1.25 Td
(Combination of sulphasalzine and methotrexate versus the single)Tj
T*
(components in early rheumatoid arthritis: a randomized, controlled,)Tj
T*
(double blind, 52 week clinical trial. Br J Rheumatol )Tj
0 Tc 0 Tw T*
(1997;36:1082-8.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
(Hoekstra, et al: Longterm MTX use)Tj
0 Tc 0 Tw 60.9375 -0.0313 Td
(2329)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
41 0 obj
<>stream
8;Z\7$#[X7%+G5@W:(.c,Ebg_,AN*EfSg;G=%=#TMXoR&fDk\Qb=:gj%BZ;D_4
(=XEJQEa1%jl+3>QnOfs#X1PeaQ`,TF,\3#&AHmq?X(Q2FkT#<%WA1TZGlK4"c1Tf
cFuL-pq2\Io5a%FqX8A5Vg.Z=Cn!guL;3t[CXRFu$FU&D&aI*upN!g&1"rm67a3<(
PE]!2$K"#;@3+0A7*dQA,IZP.R:EmZT
.;cu/mbULZ&K]ngn@-MdP[t7Bdi7_K;t'Vg"dn5tS]5hCW=1H5PSqG@m\'m2lsZ8@
LqVDYV:"Kii#8c1.k'96_G-MD)Mtk;d0cQd=qZ\R4'cj+\Q_URRbm%NA;mm388-M5
Wf8hB+CrVSR?sWQPMIY(Z^5>L`^F*nH)&IaTm/,"%)#B>:q2TPk!d`:6BcoXlpAiX
'\]no+EGFUh7fD@;,?M4SKqoeB`:bbn>o/!M,jtAU7jaNRq:`Z]E]6!gGI#80-O!l
Vg>Xam7j@))"%OAnIT`;1-:DsgXjPl4j6%CKMKuo'G#nGAaDZcim+MK\hIficL\m7
RXQ,:N!hBP,Lcdi/.KbLndBlljA:K![rUi^C7E"B9L!C'ToneY,_"nrLrAg8\~>
endstream
endobj
45 0 obj
[/Indexed/DeviceRGB 255 44 0 R]
endobj
44 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
68 0 obj
<>
endobj
76 0 obj
<>
endobj
65 0 obj
<>
endobj
103 0 obj
<>
endobj
119 0 obj
<>
endobj
64 0 obj
<>
endobj
96 0 obj
<>stream
HUkPg>#IRթ(("H @I !@%ȥ`K-+*KWu]fҗhΙysy܌aްQ`}01wm~ʠ0zZi#چ2~UjAwb
-2mssc 0l<}{N~8*9gfEwOrBnyIr8tλ^'+䚲&D0'1s? e,.'`'13y?3 DI^2/17%Ԍakxdl2ccΌ1pc1a.ͶV?'Ps:,ԤdX[-,ٱdJj:.d9:-_vfM+'!wnS 3vRaB;Ȏ:{µ;Ϊ3ڤU2qQiNrFX/(HdyRue [AMPf8%`|*]XCz#F7*6=~䘍<[WM0
iv~=w1C7f
~2CQSAz7EٱGDRywAސuY;;̓J+.
}F^*VgQN(L=*Zu͉z6}1?xPf$F)tEkGش;Y?":I$Պ
u]in뭖SA8QHp m%=Tb0csb2#9.)I~\,(WT@veñY%b2]X.-wԦgjw{1{MeO$<,Δ*sUF~;zk38eF-w:gh7yv/SH:@Q!1<'Xq437q:EzcDeuβa{vJ-4ZV*+-Ϭ//*` #]EVyLVvmq4Pj7_-9X!0}z}S%92lWT#Rג^ۑY07M<\ƣMy]e}?YXOdZo\$g+Z,'w%sXU=it{|e_v!o
hl>;B#[}5own_ѼJ$_L$w6l:KڿNX@Kh%Ћ
M꺧Gև}_/,%G~Js""" ~LװaTzw8e"#d?Ayh7IPzե˫@f1kѮ7W<